WebCytokinetics, Incorporated CYTK: Raising target price to $38.00 CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of … WebFeb 17, 2024 · Cytokinetics Financials Summary financials Revenue ( FY, 2024) $94.6M Net income ( FY, 2024) ($389.0M) Cash ( FY, 2024) $65.6M EBIT ( FY, 2024) ($324.2M) …
Did you know?
WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated … WebCytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-4.25 Market Cap $3.46 B Shares Outstanding 95.16 …
WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth … WebAug 4, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. Net loss for the second...
WebNov 4, 2024 · Inside Cytokinetics Inc's 10-Q Quarterly Report: Financial - Expense Highlight. Each of these adjustments is accounted for on a prospective basis in our liability calculation and resulted in a decline in our imputed interest rate and noncash interest expenses from 10% and $4.4 million in the second quarter of 2024 to 7.5% and $3.4 … WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share.
WebMar 31, 2024 · April 10, 2024. Cytokinetics to Participate in the 22nd Annual Needham Virtual Healthcare Conference. SOUTH SAN FRANCISCO, Calif. , April 10, 2024 (GLOBE NEWSWIRE) -- …
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential … react handler functionWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled ... react handlesubmitWebNov 3, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2024. Net loss for the third quarter was $76.1 million, or $0.95 per share, compared to net loss for the third quarter of 2024 of $3.2 million, or $0.05 per share. how to start in actingWebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity how to start imessage gamesWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated ( Nasdaq: CYTK) today announced that Robert I. Blum, … react harvardWebCYTK Cytokinetics Inc. Annual Income Statement - WSJ Subscribe Sign In Cytokinetics Inc. CYTK (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT 03/28/23 $34.98 … react has no exported member useeffectWeb2 days ago · Cytokinetics, Incorporated (CYTK) 45.71 +1.58 (3.58%) Feb 17, 2024, 4:00 PM EST - Market closed Overview Financials Statistics Forecast Dividends Profile Chart … how to start improving yourself